TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02961023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: 3-week residential phase and 12-week outpatient phase.~Residential phase~* Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.~* A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.~* 1.5 to 2 hours of exercise will be performed daily, with rest intervals.~* At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase~* Ongoing exercise prescription will be based on tolerability, progress and HR~Outpatient phase~* A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs~* Participants will be provided with a cycle ergometer, weights and a HR monitor~* Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary
Study: NCT00640627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsule once daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral placebo for 6 weeks
Study: NCT02332720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Part A: one grazoprevir 100 mg tablet taken q.d. by mouth.
Study: NCT02171312

Intervention type: BEHAVIORAL
Intervention: Routine Balance and Vestibular Testing
Description: A clinician will assess balance and vision by standard of care routine tests for neurologic function.
Study: NCT02619864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Study: NCT03125538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Together with physical rehabilitation performed with physiotherapists, participants from the experimental group will mentally rehearse 3 different locomotor exercises that they already physically performed beforehand.~Exercise 1: 10m Walk~Exercise 2: Timed Up and Go test (rise up from a chair, walk 3 meters, turn around, come back to the chair, turn around and sit down)~Exercise 3: Stairs climbing test (climb up 4 stairs, turn around, climb down the for stairs)~Two min of MIP will be scheduled 5 times/day, during rest periods, so that patients complete 10min of MIP per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Task
Description: Together with physical rehabilitation performed with physiotherapists, participants from the control group will spend equivalent time focusing on a cognitive task without impact on motor rehabilitation ((word scramble game).~Two min of this cognitive task will be scheduled 5 times/day, during rest periods, so that patients complete 10min of control task per day.
Study: NCT01985191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR405838
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT02332720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Part A: one grazoprevir 100 mg tablet taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Part A: one grazoprevir 100 mg tablet taken q.d. by mouth.
Study: NCT01231724

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allstate Nasal Spray
Description: Allstate Nasal Spray, two sprays (total 100 microliters) in each nostril.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: 2 sprays in each nostril
Study: NCT02022280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin pill
Study: NCT01371110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Midazolam
Description: Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.
Study: NCT02894944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Theragene®,Ad5-yCD/mutTKSR39rep-ADP
Description: Theragene®,Ad5-yCD/mutTKSR39rep-ADP is Adenovirus-mediated Double Suicide Gene Therapy
Study: NCT00781040

Intervention type: OTHER
Intervention: Severe sepsis vs. non-severe sepsis
Description: To compare these two groups
Study: NCT02332720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Part A: one grazoprevir 100 mg tablet taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Part A: two or three uprifosbuvir 150 mg (300 or 450 mg total daily dose) tablets taken q.d. by mouth.
Study: NCT04173780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0.01%
Description: 1 drop per day in both eyes for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 drop per day in both eyes for 1 year
Study: NCT04670952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Pressure Laparoscopic Cholecystectomy
Description: Low Pressure Laparoscopic Cholecystectomy (10mmHg) is set as the experimental group.
Study: NCT02332720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Part A: two or three uprifosbuvir 150 mg (300 or 450 mg total daily dose) tablets taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Part A: two or three uprifosbuvir 150 mg (300 or 450 mg total daily dose) tablets taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Part A: two or three uprifosbuvir 150 mg (300 or 450 mg total daily dose) tablets taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: one elbasvir 50 mg tablet taken q.d. by mouth.
Study: NCT04670952

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Pressure Laparoscopic Cholecystectomy
Description: Standard Pressure Laparoscopic Cholecystectomy (14mmHg) is set as the control group.
Study: NCT01113385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Galactose
Description: Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.
Study: NCT03813901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Samalochana Counselling
Description: Counselling program was individual, based on advaita vedanta and traditional philosophical grounds to answer individual fears, concerns,conflicts and difficulties in order to cope and recover.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait list control
Description: Wait list had no intervention offered during the study period. Afterwards, they were offered the counselling for the same duration.
Study: NCT02547415

Intervention type: OTHER
Intervention: questionnaires and psychological testing
Description: Child/adolescent and parents interview and consultation with both a physician and a psychologist for a somatic and pain indicators assessment within an usual setting.~Then, parents and child or adolescent are interviewed separately using different psychological instruments with only a psychologist:~* Psychological (cognitive and projective evaluation) : Intellectual Quotient, mental flexibility, projective evaluation with Rorschach and Thematic Apperception Test, parents and children attachment questionnaires~* Psychopathological: anxiety and depression questionnaires, psychiatric disorders evaluation, quality of life, life events questionnaires, family functioning interview.
Study: NCT03172923

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sliding hip screw
Description: fixation of the fracture with a sliding hip screw

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intramedullary nial
Description: fixation of the fracture with an intramedullary nail
Study: NCT03146455

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02332720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: one elbasvir 50 mg tablet taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Part A: six ruzasvir 10 mg (60 mg total daily dose) capsules taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Part A: six ruzasvir 10 mg (60 mg total daily dose) capsules taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.
Study: NCT01786135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD19A
Description: SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
Study: NCT03377543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81mg aspirin pill daily at bedtime over a 25 day period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81mg aspirin pill daily at bedtime over a 25 day period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 81mg non-active pill that looks like aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 81mg non-active pill that looks like aspirin
Study: NCT02336243

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Description: Docosahexaenoic acid (DHA), 600 mg per day. Each woman will take three DHA capsules per day (200 mg each), as early in gestation as possible and until the end of pregnancy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Docosahexaenoic acid (DHA))
Description: Each women allocated to the placebo group, will receive three placebo capsules per day. The placebo capsules will have same size, aspect and flavor than the DHA capsules.
Study: NCT04021810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) and patient education
Description: Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) and patient education
Description: Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device
Description: Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Advancement Device
Description: Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas
Study: NCT02984657

Intervention type: PROCEDURE
Intervention: Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.
Description: RTP, reverse Trendelenburg positioning

Intervention type: PROCEDURE
Intervention: Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.
Description: RTP, reverse Trendelenburg positioning
Study: NCT02396654

Intervention type: OTHER
Intervention: 2D and 5D LB ultrasound comparison for fetal weight estimation
Description: 2D and 5DUS LB will be done for term pregnant women and fetal weight will be estimated by the hadlock formula. Accuracy of estimated fetal weight by both techniques will be compared to actual birth weight.
Study: NCT00510094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friend to Friend program
Description: Friend to Friend arm is a social information processing group treatment to help aggressive girls learn better social problem solving and decision making choices. Participants will learn how to identify signs of physiological arousal, evaluate others' intentions, react to a potential conflict situation, and generate and evaluate alternatives. Treatment sessions are twice per week (30 to 40 minutes per session) for ten weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational attention control intervention
Description: Psychoeducational attention control group also meets two times per week for 10 weeks to control for nonspecific factors of treatment. Participants learn homework, study skills, and organizational skills.
Study: NCT00677833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin plus Chloroquine
Description: Combination of Azithromycin plus Chloroquine Azithromycin (\~30 mg/kg) + chloroquine (\~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
Study: NCT02925910

Intervention type: DEVICE
Group type: OTHER
Intervention: Shock absorbing wheelchair
Description: 2 randomised groups will try the softwheel wheelchair compare to regular one, but in different order.

Intervention type: DEVICE
Group type: OTHER
Intervention: Shock absorbing wheelchair
Description: 2 randomised groups will try the softwheel wheelchair compare to regular one, but in different order.
Study: NCT03432364

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ST-400 Investigational product
Description: Single dose of ST-400 following chemotherapy conditioning with busulfan
Study: NCT03288610

Intervention type: DIAGNOSTIC_TEST
Intervention: Preoperative copeptin level
Description: Measure of plasmatic copeptin from preoperative samples retained in a biorepository. Physicians are blinded to the result.
Study: NCT03236298

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CADD-Solis Ambulatory Infusion System
Description: The CADD-Solis pump will administer programmed intermittent boluses of 0.0625% Bupivacaine plus fentanyl 2mcg/ml.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CADD-Solis Ambulatory Infusion System
Description: The CADD-Solis pump will administer programmed intermittent boluses of 0.0625% Bupivacaine plus fentanyl 2mcg/ml.
Study: NCT01993225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 12.5 mg/25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel 1.62%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Study: NCT04646655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: subcutaneous injections
Study: NCT04493216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 was available as a 25 mg and 100 mg tablets to be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 was available as a 25 mg and 100 mg tablets to be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 was available as a 25 mg and 100 mg tablets to be administered via oral route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/3TC
Description: ABC/3TC was available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/3TC
Description: ABC/3TC was available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/3TC
Description: ABC/3TC was available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/3TC
Description: ABC/3TC was available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TAF
Description: FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TAF
Description: FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TAF
Description: FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TAF
Description: FTC/TAF was available as emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet to be administered via oral route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: Dolutegravir was available as a 50 mg tablet to be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching GSK3640254 was administered in the form of tablets via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching GSK3640254 was administered in the form of tablets via oral route.
Study: NCT00770107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine
Description: Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, for a duration of 4 weeks
Study: NCT00900874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: two puffs (100 microgram each of salbutamol) by MDI and spacer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 2 puffs (6 µg /puff) by MDI and spacer
Study: NCT02808936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: three cycles of ischemia (5 min) / reperfusion (5 min) of available upper or lower limb with an automated machine using blood pressure cuff

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: The patients had the same pneumatic cuff around the upper arm and similar maneuvers were performed, but pressure was not applied to the cuff.
Study: NCT01224301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School based flu vaccine: Low intensity
Description: Interventions: Parents of children in Low Intensity Notification schools got less than 3 communications from schools describing influenza vaccine and the clinics, and consent forms sent home one.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School based flu vaccine: High intensity
Description: Interventions: Parents in high intensity schools have 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
Study: NCT02366910

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.
Study: NCT01792479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIND-014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIND-014
Study: NCT01907191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: (Ultrasound guided injection of liposomal bupivacaine) for patients undergoing hip arthroscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: (around the anterior, lateral and medial aspect of hip joint) for patients undergoing hip arthroscopy
Study: NCT01788865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cSEMS(Covered self-expandable dual-layered metal stent) implant
Study: NCT04657744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sphingomod
Description: 1 capsule contains 0.5 mg Fingolimod

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gilenya
Description: 1 capsule contains 0.5 mg Fingolimod
Study: NCT01082094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACRX-100
Description: Three cohorts (16 total subjects) will be studied. There will be no concurrent controls. The dose will be escalated by increasing the total amount of ACRX-100 delivered per subject from low dose (n=4 subjects) to middle dose (n=6 subjects) to high dose (n=6 subjects). ACRX-100 will be injected directly into the myocardium as a single dose at multiple sites through a percutaneous, left ventricular approach using a needle injection catheter.
Study: NCT04042857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Science Treatment Gel
Description: Next Science Treatment Gel will be applied after nail surface nail-filing and/or debridement.